8-K/AAcquisitions & DispositionsExhibits & Filings

TERADYNE, INC 8-K/A Report, Acquisition Completed (Apr 8, 2008)

Filed April 8, 2008For Securities:TER

Summary

This Form 8-K/A filing from Teradyne, Inc. serves as an amendment to a previous 8-K filed on January 25, 2008, regarding the acquisition of Nextest Systems Corporation. The primary purpose of this amendment is to provide the necessary financial statements and pro forma financial information pertaining to the acquired Nextest business, as required by SEC regulations. Investors can find the unaudited interim condensed consolidated financial statements of Nextest and its audited consolidated financial statements, along with pro forma combined financial statements for Teradyne, included as exhibits to this filing. This supplemental filing is crucial for a comprehensive understanding of the financial impact of the Nextest acquisition on Teradyne. It allows stakeholders to assess the financial health and performance of the acquired entity and to evaluate the combined entity's projected financial position. Investors should review these newly provided financial details to gain a clearer picture of the acquisition's accretion or dilution and its potential contribution to Teradyne's future results.

Key Highlights

  • 1Teradyne, Inc. is filing an amendment to its previous Form 8-K to include financial information related to the acquisition of Nextest Systems Corporation.
  • 2This filing supplements the original report from January 25, 2008, by providing required financial statements and pro forma data.
  • 3Key exhibits include unaudited and audited financial statements of Nextest Systems Corporation.
  • 4Unaudited pro forma condensed combined financial statements for Teradyne, reflecting the Nextest acquisition, are also included.
  • 5The filing incorporates Nextest's financial statements by reference to its previously filed 10-Q and 10-K reports.
  • 6This amendment is essential for investors to conduct a thorough financial analysis of the Nextest acquisition's impact on Teradyne.
  • 7The amendment addresses the financial reporting requirements under Item 9.01 of Form 8-K.

Frequently Asked Questions